In an attempt to reconcile these findings with those from the present study, it can be speculated that platinum-etoposide chemotherapy is more effective in G3 NET or NEC with Ki67 ≥ 40–55%, whereas other chemotherapy regimens, such as FOLFOX/XELOX or CAPTEM might be more active in tumors with lower Ki67. This evidence concerns the gene MKI67 and neuroendocrine carcinoma.